SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company founded in Switzerland in 2011. It specializes in data-driven medicine using advanced artificial intelligence and multimodal data analytics. The company is headquartered in Rolle, Switzerland, with additional offices in Boston, Massachusetts, and France. SOPHiA GENETICS originated as a spin-off from the Swiss Federal Institute of Technology and the University of Lausanne. The core offering of SOPHiA GENETICS is the SOPHiA DDM™ platform, an AI-powered software solution that analyzes complex health data, including genomics and clinical data. This platform helps healthcare institutions make informed decisions for diagnosing and treating various medical conditions, including cancer and rare inherited disorders. The platform is utilized by over 770 healthcare institutions across 85 countries, analyzing millions of patient genomic profiles. SOPHiA GENETICS collaborates with hospitals, clinical laboratories, biopharma institutions, and research organizations to enhance diagnostics, support drug discovery, and advance research in genomics and radiomics. The company has achieved significant growth through funding, strategic partnerships, and an IPO on Nasdaq in 2021.